(NASDAQ: EOLS) Evolus's forecast annual revenue growth rate of 27.93% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 34.65%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.4%.
Evolus's revenue in 2026 is $285,823,000.On average, 9 Wall Street analysts forecast EOLS's revenue for 2026 to be $22,978,613,428, with the lowest EOLS revenue forecast at $20,842,153,347, and the highest EOLS revenue forecast at $24,800,697,556. On average, 9 Wall Street analysts forecast EOLS's revenue for 2027 to be $28,939,440,765, with the lowest EOLS revenue forecast at $24,361,219,421, and the highest EOLS revenue forecast at $32,826,035,013.
In 2028, EOLS is forecast to generate $39,562,755,164 in revenue, with the lowest revenue forecast at $32,898,633,171 and the highest revenue forecast at $47,208,896,885.